Experimental mRNA therapy targets Hard-to-Treat autoimmune conditions
Disease control
Recruiting now
This early-stage study is testing a new mRNA-based treatment called HN2301 in people with autoimmune diseases including lupus, scleroderma, and rheumatoid arthritis. The main goal is to check if the treatment is safe and well-tolerated in 30 participants who haven't responded wel…
Phase: NA • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC